<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consumption of coffee, tea, chocolate, or cola during the 24 hours that precede the test.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the plasma concentrations of lithium</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NORFLOXACINE" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of caffeine.</COMMENT>
</INTERACTION>
</INTERACTIONS>
